Noviski, Mark

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 175

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Zhang, D., Harris, H. M., Chen, J., Judy, J., James, G., Kelly, A., McIntosh, J., Tenn-McClellan, A., Ambing, E., Tan, Y. S., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 35